Synonyms: compound 195 [WO2021113557A1] | NX5948
Compound class:
Synthetic organic
Comment: NX-5948 (Nurix Therapeutics) is an oral BTK protein degrader. It was designed as an alternative to BTK inhibitors for potential to treat B cell malignancies, including those that carry BTK mutations which confer resistance to existing BTK inhibitors [1-2]. In contrast to NX-2127 which degrades both BTK and IKZF3, NX-5948 selectively degrades BTK. We believe NX-5948 is compound 195 in patent WO2021113557A1 [3].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Ligand families/groups | PROTACs, molecular glues and other degraders |
Synonyms ![]() |
compound 195 [WO2021113557A1] | NX5948 |
Database Links ![]() |
|
GtoPdb PubChem SID | 485206019 |
PubChem CID | 156464216 |
Search Google for chemical match using the InChIKey | HPTPDBYCFHFWJG-CWTKIQHKSA-N |
Search Google for chemicals with the same backbone | HPTPDBYCFHFWJG |
UniChem Compound Search for chemical match using the InChIKey | HPTPDBYCFHFWJG-CWTKIQHKSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | HPTPDBYCFHFWJG-CWTKIQHKSA-N |